Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial of REC-603

Next Previous
Trial Profile

A phase III trial of REC-603

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs REC 603 (Primary)
  • Indications Cervical cancer; Genital warts; Human papillomavirus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Jiangsu Recbio Technology

Most Recent Events

  • 20 Mar 2024 According to a Jiangsu Recbio Technology media release, study has completed the 24th month follow-up visit and are conducting the 30th month follow-up visit observation. Company plan to take the pathological endpoint for interim analysis and submit BLA application after meeting the conditions.
  • 10 Aug 2022 According to a Jiangsu Recbio Technology media release, the company has recently completed the subject enrollment and first dose vaccination in respect of immuno-bridging study. Follow-up on the subjects of REC603's efficacy trial is being conducted in accordance with the clinical protocol.
  • 24 Mar 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top